Accepted for/Published in: JMIR mHealth and uHealth
Date Submitted: Apr 6, 2020
Date Accepted: Sep 7, 2020
Opportunities for Mobile App–Based Adherence Support for Child Tuberculosis in South Africa: Viewpoint
ABSTRACT
Tuberculosis (TB) is the number one infectious cause of death globally. Young children, generally under the age of five years, are at highest risk of progressing from TB infection to TB disease and of developing the most severe forms of TB. Most current TB drug formulations have poor acceptability among children and require consistent adherence for prolonged periods of time. These challenges complicate children’s adherence to treatment and caregivers’ daily administration of the drugs. Rapid developments in mobile technologies and apps present opportunities for using widely available technology to support national TB programs and patient treatment adherence. Pilot studies have demonstrated that mobile apps are a feasible and acceptable means of enhancing children’s treatment adherence for other chronic conditions. Despite this, no mobile apps have been developed for children that aim to promote adherence to TB treatment. In this paper we draw on our experiences of researching in clinical pediatric TB studies in South Africa. We present hypothetical scenarios of children’s adherence to TB medication to suggest priorities for how a mobile–based app that incorporates behavioral and educational strategies could address some of the adherence support gaps faced by children diagnosed with TB. We argue that a mobile–based app has the potential to lessen some of the negative experiences that children associate with taking TB treatment and to facilitate a more positive treatment adherence experience for children and their caregivers.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.